Insamo is a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity. The founding team has deep scientific roots owing to time spent training in the frontier labs of David Baker at the University of Washington and Hiroaki Suga at the University of Tokyo.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/21/24 | $12,000,000 | Seed |
Axial VC BEVC Civilization Ventures MRL Ventures Fund Playground Global Sahsen Ventures VenBio | undisclosed |
